(Q61707445)
Statements
CONCERTO (English)
0 references
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (English)
0 references
20 February 2013
0 references
13 April 2015
0 references
2,199
0 references
18 year
0 references
55 year
0 references